PABCX Performance — PGIM Balanced Fund, Class C
Data updated: 2026-08-26
PABCX returned +7.12% year to date and +16.25% over one year to Jun 2026. Annualised returns are +13.53% over 3 years and +6.68% over 5 years. The fund beat its Moderate Allocation category average: $100 invested three years ago grew to $146, against $141 for the category, and to $116 over one year, against $115. Volatility over the past three years was 9.42% a year. In the 12 months to Jun 2026 the fund lost a net $1.2M, and assets reached $1.09B.
PABCX Growth of $100
What $100 invested in PGIM Balanced Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Moderate Allocation category average over the same months.
| Period | PABCX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $116 | $115 |
| 3 years (Jul 2023 – Jun 2026) | $146 | $141 |
| 5 years (Jul 2021 – Jun 2026) | $138 | $133 |
| Since data start (Jul 2019 – Jun 2026) | $173 | $169 |
PABCX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +7.12% |
| 1 year | +16.25% |
| 3 years (annualised) | +13.53% |
| 5 years (annualised) | +6.68% |
PABCX Annual Returns
Calendar-year total returns of PGIM Balanced Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +7.12% |
| 2025 | +14.66% |
| 2024 | +12.16% |
| 2023 | +15.85% |
| 2022 | −16.87% |
| 2021 | +13.51% |
| 2020 | +8.06% |
| 2019 (Jul–Dec) | +6.35% |
PABCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.8% | +1.1% | −4.5% | +6.1% | +3.1% | −0.4% | — | — | — | — | — | — |
| 2025 | +2.1% | −0.2% | −3.3% | −0.3% | +3.7% | +3.7% | +0.9% | +2.4% | +2.4% | +1.5% | +0.6% | +0.6% |
| 2024 | +0.7% | +2.8% | +2.8% | −3.6% | +3.7% | +1.7% | +1.8% | +1.7% | +1.5% | −2.1% | +3.1% | −2.3% |
| 2023 | +5.4% | −2.5% | +2.0% | +0.6% | −0.6% | +4.1% | +2.1% | −1.5% | −3.5% | −2.5% | +7.3% | +4.6% |
| 2022 | −3.3% | −2.0% | +0.4% | −6.3% | +0.4% | −6.7% | +5.6% | −3.3% | −7.8% | +4.0% | +5.3% | −3.5% |
| 2021 | +0.1% | +1.0% | +2.7% | +3.0% | +1.2% | +0.7% | +1.3% | +1.4% | −3.2% | +3.0% | −1.1% | +2.9% |
| 2020 | −0.3% | −5.3% | −11.8% | +8.4% | +3.5% | +2.5% | +3.5% | +3.0% | −2.7% | −1.7% | +7.5% | +2.9% |
| 2019 | — | — | — | — | — | — | +0.7% | −1.0% | +1.2% | +1.5% | +2.3% | +1.6% |
PABCX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 9.42%
- 3-year Sharpe ratio: 0.96 (vs 4.5% risk-free rate)
- Best month: +7.32% (Nov 2023)
- Worst month: −4.52% (Mar 2026)
PABCX Fund Flows
Monthly money in and out of PGIM Balanced Fund, from SEC Form N-PORT.
- 12-month net flow: −$1.2M
- 12-month gross sales (incl. reinvestments): $203.4M
- Sales ÷ redemptions: 0.99×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $14.2M | $19.0M | −$4.8M |
| May 2026 | $6.4M | $16.4M | −$10.1M |
| Apr 2026 | $9.8M | $18.3M | −$8.5M |
| Mar 2026 | $10.4M | $15.5M | −$5.2M |
| Feb 2026 | $7.9M | $15.3M | −$7.4M |
| Jan 2026 | $9.7M | $14.6M | −$4.9M |
| Dec 2025 | $98.2M | $26.6M | $71.5M |
| Nov 2025 | $6.5M | $20.7M | −$14.2M |
| Oct 2025 | $7.8M | $14.9M | −$7.1M |
| Sep 2025 | $16.8M | $16.2M | $567K |
| Aug 2025 | $10.0M | $13.2M | −$3.2M |
| Jul 2025 | $5.8M | $13.8M | −$8.0M |
PABCX Assets Under Management
Net assets of PGIM Balanced Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $1.09B |
| 2026-03-31 | $1.02B |
| 2025-12-31 | $1.06B |
| 2025-09-30 | $1.06B |
| 2025-06-30 | $1.01B |
| 2025-03-31 | $971.10M |
| 2024-12-31 | $1.00B |
| 2024-09-30 | $1.03B |
| 2024-06-28 | $1.00B |
| 2024-03-28 | $1.01B |
| 2023-12-29 | $962.03M |
| 2023-09-29 | $895.49M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.